Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Adalimumab Dose Adjustment for Pediatric Uveitis
NCT07699107Phase 4Not yet recruiting
- Start
- Sep 2026
- Primary completion
- May 2030
- Countries
- 3
01
Overview
Phase 4, randomised trial of adalimumab in juvenile idiopathic arthritis-associated uveitis (JIA-U) and anterior uveitis (AU) (4 arms). Primary endpoint: Cumulative Incidence of Treatment Failure at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)anterior uveitis (AU)
Beyond the preview
Go deeper on NCT07699107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699107.